Part 3/11:
Factor 8 naturally has a short lifespan of about two to three days, requiring frequent infusions to maintain effectiveness. The advent of HemLibra, which lasts about a month, has significantly reduced the frequency of infusions and the number of spontaneous bleeds, allowing for greater freedom and reduced injury.
However, this treatment comes with challenges. Despite the longer-lasting efficacy, when bleeds occur, the family must administer high-dose Factor 8 infusions, which are costly and sometimes difficult to procure. The narrator emphasizes the financial burden, with monthly medication costs explained in detail, showcasing the profound economic impact.